Inflammation as cause for scar cancers of the lung

1. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr
Cancer Ther 2003;2:238–246.
2. Ji H, Houghton AM, Mariani TJ, et al. K-ras activation generates an
inflammatory response in lung tumors. Oncogene 2006;25:2105–2112.
3. Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target
of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic
K-ras. Cancer Res 2005;65:3226–3235.
4. Lin EY, Nguyen AV, Russell RG, et al. Colony-stimulating factor 1
promotes progression of mammary tumors to malignancy. J Exp Med
2001;193:727–740.
5. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays
a critical role in tumor growth and angiogenesis. Cancer Cell 2004;
6:447–458.
6. Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a
double-edged sword. Cancer Cell 2007;12:300–301.
7. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch.
Nat Rev Cancer 2003;3:401–410.
8. Dolberg DS, Hollingsworth R, Hertle M, et al. Wounding and its role
in RSV-mediated tumor formation. Science 1985;230:676–678.
9. Sappino AP, Skalli O, Jackson B, et al. Smooth-muscle differentiation
in stromal cells of malignant and non-malignant breast tissues. Int J
Cancer 1988;41:707–712.
10. Ronnov-Jessen L, Petersen OW. Induction of alpha-smooth muscle
actin by transforming growth factor-beta 1 in quiescent human breast
gland fibroblasts. Implications for myofibroblast generation in breast
neoplasia. Lab Invest 1993;68:696–707.
11. Lohr M, Schmidt C, Ringel J, et al. Transforming growth factor-beta1
induces desmoplasia in an experimental model of human pancreatic
carcinoma. Cancer Res 2001;61:550–555.
12. Bronzert DA, Pantazis P, Antoniades HN, et al. Synthesis and secretion
of platelet-derived growth factor by human breast cancer cell lines. Proc
Natl Acad Sci U S A 1987;84:5763–5767.
13. Folkman J, Klagsbrun M, Sasse J, et al. A heparin-binding angiogenic
protein—basic fibroblast growth factor—is stored within basement
membrane. Am J Pathol 1988;130:393–400.
14. Cheng JD, Weiner LM. Tumors and their microenvironments: tilling
the soil. Commentary re: A. M. Scott et al., A Phase I dose-escalation
study of sibrotuzumab in patients with advanced or metastatic fibroblast
activation protein-positive cancer. Clin. Cancer Res., 9: 1639–1647,
2003. Clin Cancer Res 2003;9:1590–1595.
15. Adams EF, Newton CJ, Braunsberg H, et al. Effects of human breast
fibroblasts on growth and 17 beta-estradiol dehydrogenase activity of
MCF-7 cells in culture. Breast Cancer Res Treat 1988;11:165–172.
16. Camps JL, Chang SM, Hsu TC, et al. Fibroblast-mediated acceleration
of human epithelial tumor growth in vivo. Proc Natl Acad Sci U S A
1990;87:75–79.
17. Olaso E, Santisteban A, Bidaurrazaga J, et al. Tumor-dependent activation
of rodent hepatic stellate cells during experimental melanoma
metastasis. Hepatology 1997;26:634–642.
18. Nazareth MR, Broderick L, Simpson-Abelson MR, et al. Characterization
of human lung tumor-associated fibroblasts and their ability to modulate
the activation of tumor-associated T cells. J Immunol 2007;178:
5552–5562.
19. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition
is a determinant of sensitivity of non-small-cell lung carcinoma cell
lines and xenografts to epidermal growth factor receptor inhibition.
Cancer Res 2005;65:9455–9462.
20. Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression
increases sensitivity to epidermal growth factor receptor inhibitors
in lung cancer cell lines. Cancer Res 2006;66:944–950.
21. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal
phenotype determines in vitro sensitivity and predicts clinical activity of
erlotinib in lung cancer patients. Clin Cancer Res 2005;11:8686–8698.
22. Fujimoto N, Segawa Y, Takigawa N, et al. Clinical investigation of
bronchioloalveolar carcinoma: a retrospective analysis of 53 patients in
a single institution. Anticancer Res 1999;19:1369–1373.
23. Pollard JW. Tumour-educated macrophages promote tumour progression
and metastasis. Nat Rev Cancer 2004;4:71–78.
24. Chen JJ, Lin YC, Yao PL, et al. Tumor-associated macrophages: the double-
edged sword in cancer progression. J Clin Oncol 2005;23:953–964.
25. Chen JJ, Yao PL, Yuan A, et al. Up-regulation of tumor interleukin-
8 expression by infiltrating macrophages: its correlation with tumor
angiogenesis and patient survival in non-small cell lung cancer. Clin
Cancer Res 2003;9:729–737.
26. Welsh TJ, Green RH, Richardson D, et al. Macrophage and mast-cell
invasion of tumor cell islets confers a marked survival advantage in
non-small-cell lung cancer. J Clin Oncol 2005;23:8959–8967.
27. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor
microenvironments. Cancer Res 2006;66:605–612.
28. Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization:
tumor-associated macrophages as a paradigm for polarized M2 mononuclear
phagocytes. Trends Immunol 2002;23:549–555.
29. Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic
acid expression correlates with tumor progression, tumor angiogenesis,
patient survival, and timing of relapse in non-small-cell lung cancer.
Am J Respir Crit Care Med 2000;162:1957–1963.
30. Lewis JS, Landers RJ, Underwood JC, et al. Expression of vascular endothelial
growth factor by macrophages is up-regulated in poorly vascularized
areas of breast carcinomas. J Pathol 2000;192:150–158.
31. Barbera-Guillem E, Nyhus JK, Wolford CC, et al. Vascular endothelial
growth factor secretion by tumor-infiltrating macrophages essentially
supports tumor angiogenesis, and IgG immune complexes potentiate
the process. Cancer Res 2002;62:7042–7049.
32. White ES, Strom SR, Wys NL, et al. Non-small cell lung cancer
cells induce monocytes to increase expression of angiogenic activity.
J Immunol 2001;166:7549–7555.
33. Lin EY, Li JF, Gnatovskiy L, et al. Macrophages regulate the angiogenic
switch in a mouse model of breast cancer. Cancer Res 2006;66:
11238–11246.
34. Brandes ME, Finkelstein JN. Stimulated rabbit alveolar macrophages
secrete a growth factor for type II pneumocytes. Am J Respir Cell Mol
Biol 1989;1:101–109.
35. Leslie CC, McCormick-Shannon K, Cook JL, et al. Macrophages
stimulate DNA synthesis in rat alveolar type II cells. Am Rev Respir Dis
1985;132:1246–1252.
36. Takizawa H, Beckmann JD, Shoji S, et al. Pulmonary macrophages can
stimulate cell growth of bovine bronchial epithelial cells. Am J Respir
Cell Mol Biol 1990;2:245–255.
37. Schwertfeger KL, Xian W, Kaplan AM, et al. A critical role for the
inflammatory response in a mouse model of preneoplastic progression.
Cancer Res 2006;66:5676–5685.
38. Lin EY, Gouon-Evans V, Nguyen AV, et al. The macrophage growth
factor CSF-1 in mammary gland development and tumor progression.
J Mammary Gland Biol Neoplasia 2002;7:147–162.
39. Goswami S, Sahai E, Wyckoff JB, et al. Macrophages promote the invasion
of breast carcinoma cells via a colony-stimulating factor-1/epidermal
growth factor paracrine loop. Cancer Res 2005;65:5278–5283.
40. Wyckoff J, Wang W, Lin EY, et al. A paracrine loop between tumor
cells and macrophages is required for tumor cell migration in mammary
tumors. Cancer Res 2004;64:7022–7029.
41. Bellocq A, Antoine M, Flahault A, et al. Neutrophil alveolitis in bronchioloalveolar
carcinoma: induction by tumor-derived interleukin-8
and relation to clinical outcome. Am J Pathol 1998;152:83–92.
42. Wislez M, Massiani MA, Milleron B, et al. Clinical characteristics of pneumonic-
type adenocarcinoma of the lung. Chest 2003;123:1868–1877.
43. Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic
expression of interleukin-8, CXCR1, and CXCR2 correlates with cell
proliferation and microvessel density in prostate cancer. Clin Cancer Res
2005;11:4117–4127.
44. Schadendorf D, Moller A, Algermissen B, et al. M. IL-8 produced
by human malignant melanoma cells in vitro is an essential autocrine
growth factor. J Immunol 1993;151:2667–2675.
45. Zhu YM, Webster SJ, Flower D, et al. Interleukin-8/CXCL8 is a growth
factor for human lung cancer cells. Br J Cancer 2004;91:1970–1976.
46. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features
associated with epidermal growth factor receptor gene mutations
in lung cancers. J Natl Cancer Inst 2005;97:339–346.
47. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression
of lung adenocarcinomas by regulation of a K-ras transgene in
the presence and absence of tumor suppressor genes. Genes Dev 2001;
15:3249–3262.
48. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an
endogenous K-ras oncogene is highly dependent on cellular context.
Cancer Cell 2003;4:111–120.
49. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation
and progression using conditional expression of oncogenic K-ras. Genes
Dev 2001;15:3243–3248.
50. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the
K-ras oncogene causes early onset lung cancer in mice. Nature 2001;
410:1111–1116.
51. Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in
survival of patients with lung cancer: a systematic review of the literature
with meta-analysis. Br J Cancer 2005;92:131–139.
52. Pao W, Wang TY, Riely GJ, et al. KRAS Mutations and Primary
Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib. PLoS
Med 2005;2:E17.
53. Keane MP, Belperio JA, Xue YY, et al. Depletion of CXCR2 inhibits
tumor growth and angiogenesis in a murine model of lung cancer.
J Immunol 172:2853–2860.
54. Wislez M, Fujimoto N, Izzo JG, et al. High expression of ligands for
chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by
oncogenic kras. Cancer Res 2006;66:4198–4207.
55. Wislez M, Fleury-Feith J, Rabbe N, et al. Tumor-derived granulocytemacrophage
colony-stimulating factor and granulocyte colony- stimulating
factor prolong the survival of neutrophils infiltrating bronchoalveolar subtype
pulmonary adenocarcinoma. Am J Pathol 2001;159:1423–1433.
56. Jackson JH, Vollenweider M, Hill J, et al. Stimulated human leukocytes
cause activating mutations in the K-ras protooncogene. Oncogene
12;14(23):2803–2808
57. Weitberg AB, Weitzman SA, Destrempes M, et al. Stimulated human
phagocytes produce cytogenetic changes in cultured mammalian cells.
N Engl J Med 1983;308(1):26–30.
58. Wislez M, Rabbe N, Marchal J, et al. Hepatocyte growth factor production
by neutrophils infiltrating bronchioloalveolar subtype pulmonary
adenocarcinoma: role in tumor progression and death. Cancer Res
2003;63:1405–1412.
59. Wislez M, Antoine M, Rabbe N, et al. Neutrophils promote aerogenous
spread of lung adenocarcinoma with bronchioloalveolar carcinoma
features. Clin Cancer Res 2007;13:3518–3527.
60. Hoshi R, Tsuzuku M, Horai T, et al. Micropapillary clusters in earlystage
lung adenocarcinomas: a distinct cytologic sign of significantly
poor prognosis. Cancer 2004;102:81–86.
61. Takanami I, Takeuchi K, Naruke M. Mast cell density is associated
with angiogenesis and poor prognosis in pulmonary adenocarcinoma.
Cancer 2000;88(12):2686–2692.
62. Ibaraki T, Muramatsu M, Takai S, et al. The relationship of tryptaseand
chymase-positive mast cells to angiogenesis in stage I non-small
cell lung cancer. Eur J Cardiothorac Surg 2005;28:617–621.
63. Tomita M, Matsuzaki Y, Onitsuka T. Correlation between mast cells
and survival rates in patients with pulmonary adenocarcinoma. Lung
Cancer 1999;26:103–108.
64. Imada A, Shijubo N, Kojima H, et al. Mast cells correlate with angiogenesis
and poor outcome in stage I lung adenocarcinoma. Eur Respir J
2000;15:1087–1093.
65. Chiodoni C, Paglia P, Stoppacciaro A, et al. Dendritic cells infiltrating
tumors cotransduced with granulocyte/macrophage colony-stimulating
factor (GM-CSF) and CD40 ligand genes take up and present endogenous
tumor-associated antigens, and prime naive mice for a cytotoxic
T lymphocyte response. J Exp Med 1999;190(1):125–133.
66. Yang SC, Batra RK, Hillinger S, et al. Intrapulmonary administration
of CCL21 gene-modified dendritic cells reduces tumor burden in
spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006;
66:3205–3213.
67. Vicari AP, Chiodoni C, Vaure C, et al. Reversal of tumorinduced
dendritic cell paralysis by CpG immunostimulatory oligonucleotide
and anti-interleukin 10 receptor antibody. J Exp Med
2002;196:541–549.
68. Guiducci C, Vicari AP, Sangaletti S, et al. Redirecting in vivo elicited
tumor infiltrating macrophages and dendritic cells towards tumor rejection.
Cancer Res 2005;65:3437–3446.
69. Restifo NP, Esquivel F, Kawakami Y, et al. Identification of human cancers
deficient in antigen processing. J Exp Med 1993;177:265–272.
70. Zang X, Allison JP. The b7 family and cancer therapy: costimulation
and coinhibition. Clin Cancer Res 2007;13:5271–5279.
71. Batra RK, Lin Y, Sharma S, et al. Non-small cell lung cancer- derived
soluble mediators enhance apoptosis in activated T lymphocytes
through an I kappa B kinase-dependent mechanism. Cancer Res 2003;
63:642–646.
72. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from
lung cancer patients directly inhibit autologous T cell proliferation.
J Immunol 2002;168: 4272–4276.
73. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted
by chronic inflammation is B lymphocyte dependent. Cancer
Cell 2005;7:411–423.
74. Bramhall SR, Hallissey MT, Whiting J, et al. Marimastat as maintenance
therapy for patients with advanced gastric cancer: a randomised
trial. Br J Cancer 2002;86:1864–1870.
75. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebocontrolled,
randomised study comparing gemcitabine and marimastat
with gemcitabine and placebo as first line therapy in patients with advanced
pancreatic cancer. Br J Cancer 2002;87:161–167.
76. Miller KD, Gradishar W, Schuchter L, et al. A randomized phase II
pilot trial of adjuvant marimastat in patients with early-stage breast
cancer. Ann Oncol 2002;13:1220–1224.
77. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized,
double-blind, placebo-controlled trial of marimastat after response to
first-line chemotherapy in patients with small-cell lung cancer: a trial of
the National Cancer Institute of Canada-Clinical Trials Group and the
European Organization for Research and Treatment of Cancer. J Clin
Oncol 2002;20:4434–4439.
78. Bissett D, O’Byrne KJ, von Pawel J, et al. Phase III study of matrix
metalloproteinase inhibitor prinomastat in non-small-cell lung cancer.
J Clin Oncol 2005;23:842–849.
79. Smylie M, Mercier R, Aboulafia D. Phase III study of the matrix metalloprotease
(MMP) inhibitor prinomastat in patients having advanced nonsmall
cell lung cancer. [Abstract]. Proc Am Soc Clin Oncol 2001;20:1226.
80. Scott AM, Wiseman G, Welt S, et al. A Phase I dose-escalation study of
sibrotuzumab in patients with advanced or metastatic fibroblast activation
protein-positive cancer. Clin Cancer Res 2003;9:1639–1647.
81. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med 2004;350:2335–2342.
82. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;
355:2542–2550.
83. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebocontrolled
study of thalidomide in extensive-disease small-cell lung
cancer after response to chemotherapy: an intergroup study FNCLCC
cleo04 IFCT 00–01. J Clin Oncol 200725:3945–3951.
84. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced
risk of fatal colon cancer. N Engl J Med 1991;325:1593–1596.
85. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of
colorectal adenomatous polyps. N Engl J Med 2006;355:885–895.
86. Gridelli C, Gallo C, Ceribelli A, et al. Factorial phase III randomised
trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced
non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC
(GECO) study. Lancet Oncol 2007;8:500–512.
87. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated
with rofecoxib in a colorectal adenoma chemoprevention trial.
N Engl J Med 2005;352:1092–1102.